- LOADING DOCK-->
DICE DICE Therapeutics, Inc.
$29.46 0.79 (+2.76%)11:13 AM 03/31/23
#16042 Mar 31, 2023 Report
Reply Share
#2068 Jun 21, 2023 Report
Reply Share 
stonedinvestor- 34,926
Posts - 2,366
Likes
But this DICE it maybe last chance express here--
DICE DICE Therapeutics, Inc.
$32.67-0.33 (-1.00%)4:00 PM 04/21/23
NASDAQ | $USD | Pre-Market: $33.50 +0.83 (+2.54%) <-------
#16817 Apr 24, 2023 Report
Reply Share
#2069 Jun 21, 2023 Report
Reply Share- 34,926
stonedinvestor- 34,926
Posts - 2,366
Likes
Can't say I did not hold your hand through the whole process.
A-DICE Therapeutics, Inc. (DICE)
NasdaqGM - NasdaqGM Real Time Price.
34.77+2.11 (+6.46%)
As of 12:06PM EDT.
- 34,926
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
BECAUSE WE NAILED THE TRADE TWICE I WANT TO NOMINATE DICE AS GBA TRADE OF THE YEAR! WE HAVE HAD LARGER WINNERS BUT IT FEELS GOOD TO GIVE THE CHILDREN SO MUCH WARNING TWICE!!! 
Intra-Cellular Therapies, Inc. (ITCI)- We left $10 on table.
NasdaqGS - NasdaqGS Real Time Price.
65.05-0.43 (-0.66%)
LET THIS COME IN MORE AND WE GET A 2ND CHANCE!!!
CF $73 <--------
HOLD?
CF CF Industries Holdings, Inc.
$70.82-1.03 (-1.43%)9:47 AM 07/10/23
NYSE | $USD | Realtime
Typical Stoney stock.
Here today, gone tomorrow.
No staying power
View attachment 317428
The readers lost everything.... and yet he bitches about my Disney call. Or PZZA which is still at $74
THIS STOCK MUST OF SPLIT?
IT'S AT A 52 WEEK HIGH AND UP 150% IN 6 MONTHS OR SO?
WHATS'S GOING ON HERE
LFMD LifeMD, Inc.
$4.920.35 (+7.66%)9:48 AM 07/10/23
NASDAQ | $USD | Realtime
Mattel, Inc. (MAT) $21.20 HOD ON THE WAY TO $25
NasdaqGS - NasdaqGS Real Time Price.
20.98+0.50 (+2.44%)
As of 09:57AM EDT.
NasdaqGS - NasdaqGS Real Time Price.
20.98+0.50 (+2.44%)
As of 09:57AM EDT.
TOUCHDOWN- HOW DID I MISS THIS.
Management Commentary
“LifeMD started the year with tremendous performance in the first quarter of 2023. We exceeded our previous guidance for both Revenue and Consolidated Adjusted EBITDA, with record performance in both metrics. Importantly, and consistent with guidance we gave throughout 2022, our telehealth business returned to meaningful double digit revenue growth with sequential revenue in the first quarter of 2023 increasing 23% versus the fourth quarter of 2022. WorkSimpli continued to outperform, achieving EBITDA margins in the first quarter exceeding 20%, while executing numerous impactful launches, including expansion of its products to numerous new languages, launching digital signature capabilities, and executing several product enhancements to its product and forms suite.” said Justin Schreiber, Chairman & CEO of LifeMD. “Looking ahead, we remain extremely well positioned to accelerate our performance in 2023 anchored by strong lifestyle healthcare brands, a rapidly growing Virtual Primary Care (VPC) platform, recent successful launches of new product offerings, a healthy B2B pipeline, a strengthened balance sheet, and a highly profitable subsidiary producing significant cash flow that can help us further accelerate the core telehealth business.”
LifeMD CFO Marc Benathen, commented: “Our first quarter performance was extremely strong, exceeding guidance on both the top- and bottom-line, while producing substantial sequential revenue growth across both our telehealth and WorkSimpli businesses. Operationally, we also achieved several record performance levels, including consolidated Gross Margins of 87%, continued reductions in our G&A, Selling & Marketing spend as a percentage of Revenue. and a 40% improvement in First Year Lifetime Patient Value (LTV). We are particularly proud to report tat net of Accounts Payable timing, LifeMD’s cash burn reduced to just $678K and we are well on our way to achieving our guidance of Free Cash Flow positivity by mid-2023. Additionally, during the quarter we completed a significant institutional debt financing arrangement with Avenue Capital, providing up to $40 million of total funding capacity, which we believe puts us a in a very strong long-term capital position when combined with our growing profits.”
Financial Guidance
For the Second Quarter 2023, the Company expects:
Management Commentary
“LifeMD started the year with tremendous performance in the first quarter of 2023. We exceeded our previous guidance for both Revenue and Consolidated Adjusted EBITDA, with record performance in both metrics. Importantly, and consistent with guidance we gave throughout 2022, our telehealth business returned to meaningful double digit revenue growth with sequential revenue in the first quarter of 2023 increasing 23% versus the fourth quarter of 2022. WorkSimpli continued to outperform, achieving EBITDA margins in the first quarter exceeding 20%, while executing numerous impactful launches, including expansion of its products to numerous new languages, launching digital signature capabilities, and executing several product enhancements to its product and forms suite.” said Justin Schreiber, Chairman & CEO of LifeMD. “Looking ahead, we remain extremely well positioned to accelerate our performance in 2023 anchored by strong lifestyle healthcare brands, a rapidly growing Virtual Primary Care (VPC) platform, recent successful launches of new product offerings, a healthy B2B pipeline, a strengthened balance sheet, and a highly profitable subsidiary producing significant cash flow that can help us further accelerate the core telehealth business.”
LifeMD CFO Marc Benathen, commented: “Our first quarter performance was extremely strong, exceeding guidance on both the top- and bottom-line, while producing substantial sequential revenue growth across both our telehealth and WorkSimpli businesses. Operationally, we also achieved several record performance levels, including consolidated Gross Margins of 87%, continued reductions in our G&A, Selling & Marketing spend as a percentage of Revenue. and a 40% improvement in First Year Lifetime Patient Value (LTV). We are particularly proud to report tat net of Accounts Payable timing, LifeMD’s cash burn reduced to just $678K and we are well on our way to achieving our guidance of Free Cash Flow positivity by mid-2023. Additionally, during the quarter we completed a significant institutional debt financing arrangement with Avenue Capital, providing up to $40 million of total funding capacity, which we believe puts us a in a very strong long-term capital position when combined with our growing profits.”
Financial Guidance
For the Second Quarter 2023, the Company expects:
- Consolidated Revenue to total between $35.0 million and $36.0 million
- Consolidated Adjusted EBITDA between $2.5 and $3.5 million
- Consolidated Revenue to total between $140.0 million and $150.0 million
- Consolidated Adjusted EBITDA between $12.0 and $18.0 million
GTBIF--
WHEN YOU LOOK THROUGH AS MANY CHARTS AS I DO YOU CAN START TO SEE MOVES BEFORE THEY HAPPEN..
https://seekingalpha.com/symbol/GTB...metric=priceReturn,total_assets,tangible_book
WHEN YOU LOOK THROUGH AS MANY CHARTS AS I DO YOU CAN START TO SEE MOVES BEFORE THEY HAPPEN..
https://seekingalpha.com/symbol/GTB...metric=priceReturn,total_assets,tangible_book